Navigation Links
FDA Approval for Lung Cancer Treatment -Avastin Along with Chemotherapy

The FDA has approved the drug bevacizumab (Avastin) for first time treatment of advanced lung cancer in conjunction with chemotherapy. // This comes after a large randomised study on lung cancer patients led by Dr.Alan Sandler, lung cancer specialist and director of Thoracic Oncology at Vanderbilt-Ingram Cancer Center.

Nearly 900 patients with non-small cell lung cancer (NSCLC) were tested during the trial. None of them had received any previous chemotherapy. Half were given Avastin along with standard chemotherapy drugs while the others were given chemotherapy alone. The study revealed that patients on Avastin survived an average of two months longer than the usual one year survival rate.

Though this does not sound wonderful, it is important to bear in mind that the results were based on average reactions. In some people the survival was even longer, while in others the tumours shrunk and disappeared. However there was no response in some patients.

Bevacizumab is a targeted drug, which means that it does not attack non-cancerous cells. It acts by stopping development of new blood vessels, which supply the tumours. The side effects are generally mild. However a unique and serious one is bleeding from the primary tumour, since the drug acts on the blood vessels; this has to be addressed.

Dr. Sandler is hopeful that the drug will prove path breaking and lead to better survival rates and also to more patients being cured if the disease is caught early. As NSCLC is the most common form of lung cancer in the US, this is encouraging news indeed.
SRM
'"/>




Page: 1

Related medicine news :

1. Approval for DNA test to detect cystic fibrosis
2. Vaccine For Cervical Cancer Awaits Approval
3. WHO Gives Its Approval For Bird Flu Test Kit
4. FDA Gives Its Approval For Inhaler
5. RotaTeq Gets US Approval
6. Better Communication With FDA Could Speed Up Approval Of New Drugs
7. Nerve Stimulator for Depression Though Not Effective Was Given Approval
8. Ranbaxy Gets USFDA Approval For Doxycycline Tablets
9. Global Education Net Pvt Medical College Gets MCI Approval
10. Approval of Drugs for the Treatment of Late-Stage Cancer
11. Lupin Gets USFDA Approval For Quinapril Tablets
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... April 28, 2017 , ... ... of the GlycoMark test throughout the Northeast U.S. , GlycoMark is the ... diabetes. The GlycoMark test provides a clinically proven one- to two-week measure of ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... ... ... Bill Howe started his sewer and drain company in 1980 focusing heavily ... team, the Bill Howe brand was born and they began cultivating their mission to ... the San Diego community in which they worked, lived and were raising their daughters. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation Limited, a leading ... Nova Skin Sciences division, recently announced the launch of Allumière Antiaging Cream, a ... of an anti-aging concentrate. , Anogeissus Leiocarpa Bark Extract and Vitamin ...
(Date:4/27/2017)... and DENVER (PRWEB) , ... April 27, 2017 ... ... Health, the nation’s leading respiratory hospital, based in Denver, Colorado, announced an agreement ... is enabled by the continuing support of the Jane and Leonard Korman Family ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, ... focused on providing the Urology, Uro/Gyn and Gynecology ... that Ash Keswani has joined the Company as ... this newly created position, Mr. Keswani will report ... CEO. "Our organization is delighted that ...
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
Breaking Medicine Technology: